BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10735894)

  • 1. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series.
    Cabelguenne A; Blons H; de Waziers I; Carnot F; Houllier AM; Soussi T; Brasnu D; Beaune P; Laccourreye O; Laurent-Puig P
    J Clin Oncol; 2000 Apr; 18(7):1465-73. PubMed ID: 10735894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck.
    Temam S; Flahault A; Périé S; Monceaux G; Coulet F; Callard P; Bernaudin JF; St Guily JL; Fouret P
    J Clin Oncol; 2000 Jan; 18(2):385-94. PubMed ID: 10637254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma.
    Blons H; Cabelguenne A; Carnot F; Laccourreye O; de Waziers I; Hamelin R; Brasnu D; Beaune P; Laurent-Puig P
    Int J Cancer; 1999 Aug; 84(4):410-5. PubMed ID: 10404095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
    Fouret P; Temam S; Charlotte F; Lacau-St-Guily J
    Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas.
    Lavieille JP; Righini C; Reyt E; Brambilla C; Riva C
    Oral Oncol; 1998 Mar; 34(2):84-92. PubMed ID: 9682769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
    Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
    Perrone F; Bossi P; Cortelazzi B; Locati L; Quattrone P; Pierotti MA; Pilotti S; Licitra L
    J Clin Oncol; 2010 Feb; 28(5):761-6. PubMed ID: 20048189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
    Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
    Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma.
    Lièvre A; Blons H; Houllier AM; Laccourreye O; Brasnu D; Beaune P; Laurent-Puig P
    Br J Cancer; 2006 Mar; 94(5):692-7. PubMed ID: 16495928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
    Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
    Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy.
    Cabelguenne A; Loriot MA; Stucker I; Blons H; Koum-Besson E; Brasnu D; Beaune P; Laccourreye O; Laurent-Puig P; De Waziers I
    Int J Cancer; 2001 Sep; 93(5):725-30. PubMed ID: 11477586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
    Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
    Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red blood cell glutathione levels before and during treatment with neoadjuvant chemotherapy cisplatin/5-fluorouracil in patients with head and neck squamous cell carcinoma.
    Massaad-Massade L; Domenge C; Rongeat S; Hassoun L; Legros MH; Ropers J; Janot F; Parise O; Gouyette A
    Anticancer Res; 1998; 18(1A):283-8. PubMed ID: 9568091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
    Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population.
    Mitra S; Banerjee S; Misra C; Singh RK; Roy A; Sengupta A; Panda CK; Roychoudhury S
    J Clin Pathol; 2007 Sep; 60(9):1040-7. PubMed ID: 17079356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
    Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
    Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 tumor suppressor protein and H-RAS oncogene in maxillofacial tumors: immunohistochemical and genetic investigation, induction chemotherapy response and prognosis evaluation.
    Cutilli T; Papola F; Di Emidio P; Corbacelli A
    J Chemother; 1998 Oct; 10(5):411-7. PubMed ID: 9822361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.
    Giatromanolaki A; Koukourakis M; Zaramboukas T; Skordalaki A; Arapantoni P; Georgoulias V; Fountzilas G
    Anticancer Res; 1998; 18(6B):4685-92. PubMed ID: 9891541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy.
    Baghi M; Mack MG; Hambek M; Bisdas S; Muerthel R; Wagenblast J; Gstoettner W; Vogl T; Knecht R
    Head Neck; 2007 Feb; 29(2):104-8. PubMed ID: 17111434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.